Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 37
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
16 to 75
Other
CGC05MK1002
NCT00188149
Last Modified:
2/12/2008
 
First Published:
11/1/2000
2.
Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 22
Other
FRE-IGR-ALCL99
EU-20031, NHL2000/06, NCT00006455
Last Modified:
8/21/2008
 
First Published:
9/1/2001
3.
Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Any age
NCI
MDA-ID-00156
NCI-3410, 3410, NCT00024167
Last Modified:
4/30/2008
 
First Published:
1/1/2002
4.
Phase III Randomized Study of Immediate Versus Deferred Adjuvant Chemotherapy After Radical Cystectomy in Patients With Stage III or IV Transitional Cell Carcinoma of the Bladder Urothelium
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Not specified
NCI, Other
EORTC-30994
ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, JUG-EORTC-30994, NORDIC-EORTC-30994, SEUG-EORTC-30994, SWOG-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756, EORTC-30994
Last Modified:
5/18/2007
 
First Published:
7/1/2002
5.
Phase III Randomized Study of Bleomycin, Doxorubicin, Etoposide, Mechlorethamine, Vinblastine, Vincristine, and Prednisone (Stanford V) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Previously Untreated Advanced Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 60
Other
BNLI-STANFORDV
EU-20206, NCT00041210
Last Modified:
4/29/2008
 
First Published:
11/1/2002
6.
Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
16 to 60
Other
EORTC-20012
GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, NCT00049595
Last Modified:
10/17/2008
 
First Published:
4/23/2003
7.
Phase III Randomized Study of Consolidation Chemotherapy Comprising Doxorubicin and Prednisone in Combination With Vincristine Versus Vinblastine in Patients With Advanced Anaplastic Large Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 21
NCI
COG-ANHL0131
NCT00059839, ANHL0131
Last Modified:
8/9/2007
 
First Published:
12/22/2005
8.
Phase III Study of Observation and/or Chemotherapy Comprising Etoposide, Carboplatin, and Bleomycin With or Without Vinblastine, Ifosfamide, and Cisplatin After Surgical Resection or Biopsy in Pediatric Patients With Extracranial Malignant Germ Cell Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 18
Other
CCLG-GC-2005-04
EUDRACT-2004-002503-33, EU-20584, NCT00274950
First Published:
2/5/2007
9.
Phase III Randomized Study of Early Fludeoxglucose F 18 Positron Emission Tomography Scan-Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Previously Untreated Supradiaphragmatic Stage I or II Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
15 to 70
Other
EORTC-20051
GELA-H10, EUDRACT-2005-002765-37, NCT00433433
Last Modified:
6/19/2008
 
First Published:
2/5/2007
10.
Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic, Treatment
Active
Under 18
Other
EURONET-PHL-C1
EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute